Experience of Vein Grafting in Goettingen Minipigs.

Tsutsumi, Hideaki; Miyawaki, Fujio; Arakawa, Hitoshi; Tsuji, Takayuki; Tanigawa, Manabu

doi:10.1538/expanim.50.191

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The end-to-side graft implantation in the pig model is an accelerated intimal hyperplasia model, which typically results in lower patency rates than porcine interpositional vein grafts (25). Although both the cell-seeded TEV and the vein grafts had an endothelial layer, there was a substantial difference in graft patency that correlated to the degree of intimal hyperplasia.…”

Section: Discussionmentioning

confidence: 99%

Decellularized tissue-engineered blood vessel as an arterial conduit

Quint¹,

Kondo²,

Manson

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

331

306

View full text Add to dashboard Cite

Arterial tissue-engineering techniques that have been reported previously typically involve long waiting times of several months while cells from the recipient are cultured to create the engineered vessel. In this study, we developed a different approach to arterial tissue engineering that can substantially reduce the waiting time for a graft. Tissue-engineered vessels (TEVs) were grown from banked porcine smooth muscle cells that were allogeneic to the intended recipient, using a biomimetic perfusion system. The engineered vessels were then decellularized, leaving behind the mechanically robust extracellular matrix of the graft wall. The acellular grafts were then seeded with cells that were derived from the intended recipient-either endothelial progenitor cells (EPC) or endothelial cell (EC)-on the graft lumen. TEV were then implanted as end-toside grafts in the porcine carotid artery, which is a rigorous testbed due to its tendency for graft occlusion. The EPC-and EC-seeded TEV all remained patent for 30 d in this study, whereas the contralateral control vein grafts were patent in only 3/8 implants. Going along with the improved patency, the cell-seeded TEV demonstrated less neointimal hyperplasia and fewer proliferating cells than did the vein grafts. Proteins in the mammalian target of rapamycin signaling pathway tended to be decreased in TEV compared with vein grafts, implicating this pathway in the TEV's resistance to occlusion from intimal hyperplasia. These results indicate that a readily available, decellularized tissue-engineered vessel can be seeded with autologous endothelial progenitor cells to provide a biological vascular graft that resists both clotting and intimal hyperplasia. In addition, these results show that engineered connective tissues can be grown from banked cells, rendered acellular, and then used for tissue regeneration in vivo.bypass graft | collagen | mechanical conditioning

show abstract

Section: Discussionmentioning

confidence: 99%

Decellularized tissue-engineered blood vessel as an arterial conduit

Quint¹,

Kondo²,

Manson

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

331

306

View full text Add to dashboard Cite

show abstract

“…Very little intimal hyperplasia was reported, which was particularly interesting in the porcine carotid artery bypass study, as this animal model is usually considered to demonstrate accelerated intimal hyperplasia formation. 70 These findings have now resulted in the undertaking of pilot studies in humans with the TEVG employed as an AVF for vascular access in patients with end-stage renal disease. Studies are ongoing with the first entrants recruited in 2012 and the results keenly anticipated.…”

Section: Techniques For Manufacturing a Tevgmentioning

confidence: 99%

The Tissue-Engineered Vascular Graft—Past, Present, and Future

Pashneh‐Tala

MacNeil

Claeyssens

2016

Tissue Engineering Part B: Reviews

651

650

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to continue for the foreseeable future. Common disorders are associated with the stenosis or occlusion of blood vessels. The preferred treatment for the long-term revascularization of occluded vessels is surgery utilizing vascular grafts, such as coronary artery bypass grafting and peripheral artery bypass grafting. Currently, autologous vessels such as the saphenous vein and internal thoracic artery represent the gold standard grafts for small-diameter vessels (<6 mm), outperforming synthetic alternatives. However, these vessels are of limited availability, require invasive harvest, and are often unsuitable for use. To address this, the development of a tissue-engineered vascular graft (TEVG) has been rigorously pursued. This article reviews the current state of the art of TEVGs. The various approaches being explored to generate TEVGs are described, including scaffold-based methods (using synthetic and natural polymers), the use of decellularized natural matrices, and tissue self-assembly processes, with the results of various in vivo studies, including clinical trials, highlighted. A discussion of the key areas for further investigation, including graft cell source, mechanical properties, hemodynamics, integration, and assessment in animal models, is then presented.

show abstract

“…[10][11][12][13][14] There have also been clinical trials for small-diameter TEVGs built on the polymer synthesis and implantation techniques previously established by using ovine, porcine, and canine models. 11,15,16 Olausson et al described a case of using decellularized donor iliac vein as a venous bypass around an obstructed extrahepatic portal vein that remained patent at 1 year of follow-up. 17 Two other clinical trials tested the potential of the Lifeline graft, consisting of endothelial cell-seeded fibroblast sheets rolled into a tube, as AV grafts in patients with ESRD.…”

Section: Introductionmentioning

confidence: 99%

Bilateral Arteriovenous Shunts as a Method for Evaluating Tissue-Engineered Vascular Grafts in Large Animal Models

Ong

Fukunishi

Liu

et al. 2017

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

There remains a need for large animal models to evaluate tissue-engineered vascular grafts (TEVGs) under arterial pressure to provide preclinical data for future potential human clinical trials. We present a comprehensive method for the interrogation of TEVGs, using an ovine bilateral arteriovenous (AV) shunt implantation model. Our results demonstrate that this method can be performed safely without complications, specifically acute heart failure, steal syndrome, and hypoxic brain injury, and it is a viable experimental paradigm. Our method allows for a non-invasive evaluation of TEVGs in terms of graft flow, graft diameter, and graft patency, while also allowing for graft needle puncture under ultrasound guidance. In addition, traditional pathological analysis, histology, and immunohistochemistry may be performed with the contralateral side providing paired control data to eliminate inter-subject variability while reducing the total number of animals. Further, we present a review of existing literature of preclinical evaluation of TEVGs in large animal models as AV conduits.

show abstract

Experience of Vein Grafting in Goettingen Minipigs.

Cited by 3 publications

References 10 publications

Decellularized tissue-engineered blood vessel as an arterial conduit

Decellularized tissue-engineered blood vessel as an arterial conduit

The Tissue-Engineered Vascular Graft—Past, Present, and Future

Bilateral Arteriovenous Shunts as a Method for Evaluating Tissue-Engineered Vascular Grafts in Large Animal Models

Contact Info

Product

Resources

About